TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25990577

Group type: EXPERIMENTAL
Intervention: LNG-IUS 52 mg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 165

Group type: COMPARATOR
Intervention: Both IUDs
Number of subjects: 165
Study: 25991083

Group type: EXPERIMENTAL
Intervention: Faldaprevir 80 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Number of subjects: 25
Study: 25991462

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 88
Study: 25992287

Group type: EXPERIMENTAL
Intervention: Mothers measuring MUAC using a colour-banded MUAC strap after minimal training
Number of subjects: 103

Group type: COMPARATOR
Intervention: Community Health Workers (CHW) following current MUAC protocols
Number of subjects: 103
Study: 25992307

Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention (microfinance loan, micro-irrigation pump, seeds, fertilizer, training)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 25992639

Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Zidovudine plus lopinavir/ritonavir
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatments duration
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Baseline CD4
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Predicted viral load at delivery
Number of subjects: 3759
Study: 25992656

Group type: EXPERIMENTAL
Intervention: Local vibration training (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 35
Study: 25993630

Group type: EXPERIMENTAL
Intervention: L-Arginine therapy (single dose and 6-week steady-state trial)
Number of subjects: 3
Study: 25993625

Group type: EXPERIMENTAL
Intervention: Ice application to the sole of the foot
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ice application to the calf
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ice application to the ankle
Number of subjects: 21
Study: 25993984

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)
Number of subjects: 106
Study: 25994184

Group type: EXPERIMENTAL
Intervention: High serum leptin levels in men
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: High serum leptin levels in women
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: High serum leptin levels in men with adjustments for traditional risk factors
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: High serum leptin levels in women with adjustments for traditional risk factors
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: High serum leptin levels in men with adjustments for PWV and IMT
Number of subjects: 720
Study: 25994356

Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: fatigue visual analogue scale (fVAS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Age and depression
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Disease activity markers (Mayo score for UC, Harvey-Bradshaw index for CD, CRP, faecal calprotectin)
Number of subjects: 81
Study: 25994566

Group type: EXPERIMENTAL
Intervention: Alcohol intake (tertile 3 vs. tertile 1)
Number of subjects: 6542
Study: 25994816

Group type: EXPERIMENTAL
Intervention: Variant rs11668344-G
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Variant rs12294104-T
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Variant rs10852344-T
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Genetic risk score from 16 variants
Number of subjects: 1790
Study: 25995224

Group type: EXPERIMENTAL
Intervention: Marrow-infiltrating lymphocytes (MILs)
Number of subjects: 25
Study: 25995289

Group type: EXPERIMENTAL
Intervention: Self-reported dietary recalls
Number of subjects: 477
Study: 25995313

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (325 mg)
Number of subjects: 10213

Group type: COMPARATOR
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 10213
Study: 25996360

Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No Total Hip Replacement (non-THR)
Number of subjects: 43
Study: 25998039

Group type: EXPERIMENTAL
Intervention: ABI ≤0.90
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: ACE inhibitors/angiotensin receptor blockers
Number of subjects: 897

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 897
Study: 25998042

Group type: EXPERIMENTAL
Intervention: Foretinib (various formulations including bisphosphate salt capsules, freebase tablets, and solution formulation)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Foretinib (solution formulation)
Number of subjects: 132
Study: 25998717

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy with the Lokomat® system (Intervention group, IG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard postoperative physiotherapy (Control group, CG)
Number of subjects: 30
Study: 25999106

Group type: EXPERIMENTAL
Intervention: iFR with a pre-specified cut-off of 0.89
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Hybrid iFR-FFR approach
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: iFR outside of treatment (≤0.85) and deferral (≥0.94) values
Number of subjects: 598
Study: 25999107

Group type: EXPERIMENTAL
Intervention: Baseline Distal-to-Aortic Pressure Ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25999108

Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve System implanted at an optimal depth (≤6 mm below the aortic annulus)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: New-onset first-degree atrioventricular block
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Patients with new PPI
Number of subjects: 194
Study: 25999183

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg pretreatment
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: DMF without ASA
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: DMF with ASA
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Slow dose titration DMF
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo ASA
Number of subjects: 173
Study: 25999292

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Atomoxetine (ATX)
Number of subjects: 267
Study: 25999401

Group type: EXPERIMENTAL
Intervention: Catheter ablation of AF
Number of subjects: 9935

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 9935

Group type: COMPARATOR
Intervention: Adjusted risk of death
Number of subjects: 9935

Group type: COMPARATOR
Intervention: Adjusted risk of cardiovascular hospitalization
Number of subjects: 9935

Group type: EXPERIMENTAL
Intervention: Incident AF ablation
Number of subjects: 9935
Study: 25999435

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg (cohort 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg (cohorts 2 and 3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IPH2101 0.2 mg/kg (cohort 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IPH2101 1 mg/kg (cohort 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IPH2101 2 mg/kg (cohort 3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Lenalidomide and IPH2101
Number of subjects: 15
Study: 25999444

Group type: EXPERIMENTAL
Intervention: Ruxolitinib, specific dosage and duration not available
Number of subjects: 0
Study: 26000222

Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 0
Study: 26000503

Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis in maternal blood samples
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis at ultrasonographic gestational ages of 8 weeks or greater
Number of subjects: 50
Study: 26001109

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 3209

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 3209
Study: 26001104

Group type: COMPARATOR
Intervention: Daytime surgery
Number of subjects: 11290

Group type: COMPARATOR
Intervention: Evening surgery
Number of subjects: 11290

Group type: COMPARATOR
Intervention: Night-time surgery
Number of subjects: 11290

Group type: COMPARATOR
Intervention: Evening surgery (adjusted)
Number of subjects: 11290

Group type: COMPARATOR
Intervention: Night-time surgery (adjusted)
Number of subjects: 11290

Group type: COMPARATOR
Intervention: ICU admission rate during daytime
Number of subjects: 11290

Group type: COMPARATOR
Intervention: ICU admission rate during evening
Number of subjects: 11290

Group type: COMPARATOR
Intervention: ICU admission rate during night-time
Number of subjects: 11290
Study: 26001509

Group type: EXPERIMENTAL
Intervention: Electrical interlead distance (EID) >84 ms
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Horizontal corrected interlead distance (HCID) >90 mm
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: EID <84 ms and HCID <90 mm
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Clinical composite score improvement after 12 months
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: EID cutoff value
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: HCID cutoff value
Number of subjects: 216
Study: 26001635

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 325
Study: 26001791

Group type: EXPERIMENTAL
Intervention: Eight-color flow cytometry
Number of subjects: 122

Group type: COMPARATOR
Intervention: Polymerase chain reaction
Number of subjects: 122
Study: 26001793

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII + antifibrinolytics
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII + platelets ± antifibrinolytics
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Platelets ± antifibrinolytics
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Antifibrinolytics alone
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Any treatment
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Adverse events related to treatments including recombinant activated factor VII
Number of subjects: 829
Study: 26001792

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa+antifibrinolytics
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Platelets±antifibrinolytics
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa+platelets±antifibrinolytics
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa, with or without platelets (±antifibrinolytics)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa+platelets+antifibrinolytics
Number of subjects: 96
Study: 26002091

Group type: EXPERIMENTAL
Intervention: Test intervention (toothpaste and toothbrushes mailed every three months, education and social support via postcards, recorded messages, and optional helpline)
Number of subjects: 21743

Group type: COMPARATOR
Intervention: Active control (kit of supplies mailed, no additional instructional information or telephone support)
Number of subjects: 21743

Group type: COMPARATOR
Intervention: Passive control (waiting list)
Number of subjects: 21743
Study: 26002711

Group type: EXPERIMENTAL
Intervention: Surgical strategies other than direct clipping
Number of subjects: 19
Study: 26002753

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 61
Study: 26002835

Group type: EXPERIMENTAL
Intervention: eA1c using MyStar Extra blood glucose meter
Number of subjects: 133
Study: 26003007

Group type: EXPERIMENTAL
Intervention: Regorafenib 60 mg/d continuously, Cisplatin 75 mg/m², Pemetrexed 500 mg/m² once every 21 days for up to 6 cycles.
Number of subjects: 9
Study: 26003997

Group type: EXPERIMENTAL
Intervention: Black obese adolescent females
Number of subjects: 61

Group type: COMPARATOR
Intervention: White obese adolescent females
Number of subjects: 61
Study: 26006067

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 iv every 21 days and eribulin 1.4 mg/m2 on day 1 and day 8 every 21 days for four cycles
Number of subjects: 30
Study: 26006114

Group type: EXPERIMENTAL
Intervention: Children with NAFLD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ob/ob mice
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ob/ob mice treated with aT
Number of subjects: 49
Study: 26006717

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of internal jugular vein
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Comparing top and bottom tertiles of JVD ratio
Number of subjects: 311
Study: 26007682

Group type: EXPERIMENTAL
Intervention: Community Level Interventions for Pre-eclampsia (CLIP) applied at community and primary health centres.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis (CEA) and qualitative thematic analysis alongside the trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured questionnaires for data collection.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus groups (FGs) with pregnant women, household male-decision makers, care providers, and district level health decision makers.
Number of subjects: 0
Study: 26009269

Group type: EXPERIMENTAL
Intervention: Saracatinib 175mg orally daily
Number of subjects: 21
Study: 26009994

Group type: EXPERIMENTAL
Intervention: siG12D-LODER™ (0.025mg, 0.75mg, and 3.0mg) plus Gemcitabine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: siG12D-LODER™ plus chemotherapy
Number of subjects: 15
Study: 26010254

Group type: EXPERIMENTAL
Intervention: Low fat dietary intervention
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low carbohydrate dietary intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 249
Study: 26010298

Group type: EXPERIMENTAL
Intervention: Olfactory cleft opacification quantified using 3D volumetric analysis and SIT-40 assessment before and after sinus surgery.
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Lund-Mackay CT scoring for sinus opacification.
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Quantitative volumetric measures of olfactory cleft opacification.
Number of subjects: 199
Study: 26010610

Group type: COMPARATOR
Intervention: HFpEF patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metabolomic fingerprint
Number of subjects: 24
Study: 26010778

Group type: EXPERIMENTAL
Intervention: HAI and systemic chemotherapy
Number of subjects: 38
Study: 26011015

Group type: EXPERIMENTAL
Intervention: Chronic rhinosinusitis (CRS) positive group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Chronic rhinosinusitis (CRS) negative group
Number of subjects: 113
Study: 26011262

Group type: EXPERIMENTAL
Intervention: Chemokine IP-10 levels
Number of subjects: 0
Study: 26011265

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Clopidogrel dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26011755

Group type: EXPERIMENTAL
Intervention: Hexyl-5-aminolaevulinate 0·2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: methyl-5-aminolaevulinate 16%
Number of subjects: 0
Study: 26011782

Group type: EXPERIMENTAL
Intervention: Intestinal manipulation (IM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical study by Berdun et al.
Number of subjects: 0
Study: 26014453

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention in a tobacco-free prison
Number of subjects: 247
Study: 26014957

Group type: EXPERIMENTAL
Intervention: Single-dose doripenem (5 mg/kg for <8 weeks and 8 mg/kg for ≥8 weeks) administered intravenously over 1 h
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Single-dose doripenem
Number of subjects: 52
Study: 26015411

Group type: EXPERIMENTAL
Intervention: Oseltamivir 3 mg/kg (cohort 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oseltamivir 2.5 mg/kg (cohort 2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oseltamivir 2 mg/kg (cohort 3)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oseltamivir (all cohorts)
Number of subjects: 65
Study: 26015461

Group type: EXPERIMENTAL
Intervention: Weight loss of 5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss of 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss of 15%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no weight loss)
Number of subjects: 0
Study: 26016860

Group type: EXPERIMENTAL
Intervention: Single MRI slice at lumbar vertebrae L3
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Single MRI slice at midthigh
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Weight loss (8.2 ± 5.2 kg) in 48 healthy volunteers
Number of subjects: 142
Study: 26016863

Group type: EXPERIMENTAL
Intervention: Higher anthocyanin intake
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: Higher flavonol intake
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: Higher intakes of apples and pears
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: Higher intakes of red wine
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: Higher intakes of strawberries
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: Higher intakes of flavan-3-ols and their polymers
Number of subjects: 2375
Study: 26016868

Group type: EXPERIMENTAL
Intervention: Opticourses intervention participants
Number of subjects: 91
Study: 26017904

Group type: EXPERIMENTAL
Intervention: FMS fatigue
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subcluster 1 (78% of total subjects)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subcluster 2 (22% of total subjects)
Number of subjects: 120
Study: 26018350

Group type: EXPERIMENTAL
Intervention: IVIg + Tocilizumab (TCZ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tocilizumab and IVIg
Number of subjects: 10
Study: 26018526

Group type: EXPERIMENTAL
Intervention: Mini Open Plating (MOP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional Open Plating (COP)
Number of subjects: 24
Study: 26018967

Group type: EXPERIMENTAL
Intervention: DFMO (difluoromethylornithine) 500-1500 mg/m2 orally twice a day for three weeks, followed by DFMO plus daily oral etoposide for additional three-week cycles.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DFMO therapy
Number of subjects: 21
Study: 26019869

Group type: EXPERIMENTAL
Intervention: ABBI
Number of subjects: 160

Group type: COMPARATOR
Intervention: SBT
Number of subjects: 160
Study: 26019883

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary interventions (PCIs) in 2013
Number of subjects: 2703

Group type: EXPERIMENTAL
Intervention: Non-reperfused patients in 2013
Number of subjects: 2703

Group type: EXPERIMENTAL
Intervention: Overall STEMI mortality rate in 2013
Number of subjects: 2703
Study: 26019881

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 64-multidetector CTCA
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Calcium score
Number of subjects: 210
Study: 26020101

Group type: EXPERIMENTAL
Intervention: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine)
Number of subjects: 100
Study: 26020107

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy
Number of subjects: 434

Group type: COMPARATOR
Intervention: Laparoscopic gastrectomy
Number of subjects: 434
Study: 26020125

Group type: EXPERIMENTAL
Intervention: Ceritinib 300 to 750 mg once daily in 21-day cycles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (maximum-tolerated dose)
Number of subjects: 20
Study: 26020123

Group type: EXPERIMENTAL
Intervention: Predictive PRF score based on seven independent risk factors: low preoperative SpO2; at least one preoperative respiratory symptom; preoperative chronic liver disease; history of congestive heart failure; open intrathoracic or upper abdominal surgery; surgical procedure lasting at least 2 hours; and emergency surgery.
Number of subjects: 5384

Group type: EXPERIMENTAL
Intervention: Predictive PRF score
Number of subjects: 5384
Study: 26020392

Group type: EXPERIMENTAL
Intervention: Workshop using interactive lecture, human model, educational film, and reference CPCR book
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: General population (G3)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2000
Study: 26020620

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26020762

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetSyn) group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Quantitative Insulin Sensitivity Check Index (as a surrogate for hepatic insulin sensitivity)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Adipo-SI and serum triglyceride levels
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Waist circumference and serum triglyceride levels
Number of subjects: 77
Study: 26020806

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m plus Gemcitabine 1000 mg/m
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 15 mg/m plus Gemcitabine 900 mg/m
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 15 mg/m plus Gemcitabine 700 mg/m
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gemcitabine 700 mg/m followed by Cabazitaxel 15 mg/m
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus Gemcitabine (all doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus Gemcitabine
Number of subjects: 18
Study: 26021417

Group type: EXPERIMENTAL
Intervention: Proceed®-mesh
Number of subjects: 210
Study: 26021444

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 39